Travere Therapeutics (TVTX) Income towards Parent Company (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Income towards Parent Company came in at -$500000.0 in Q1 2026, down 102.02% on a QoQ basis from $24.7 million in Q4 2025.
Travere Therapeutics (TVTX) Income towards Parent Company (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Income towards Parent Company data on file, last reported at -$500000.0 in Q1 2026.
- Quarterly Income towards Parent Company changed N/A year-over-year to -$500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.2 million (up 3013.96% YoY) and the FY2025 annual result came in at $24.7 million, up 2801.09% from the prior year.
- Income towards Parent Company retreated to -$500000.0 in Q1 2026, from $24.7 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $240.0 million in Q3 2023 to a low of -$1.6 million in Q4 2023.
- A 5-year average of $24.4 million and a median of $8.0 million in 2022 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company plunged 107.96% — and 2025, when it soared 164866.67%.
- Tracing TVTX's Income towards Parent Company over 5 years: stood at $19.8 million in 2022, then plunged by 107.96% to -$1.6 million in 2023, then jumped by 99.05% to -$15000.0 in 2024, then soared by 164866.67% to $24.7 million in 2025, then tumbled by 102.02% to -$500000.0 in 2026.
- The last three Income towards Parent Company figures came in at -$500000.0 (Q1 2026), $24.7 million (Q4 2025), and -$15000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -500,000.00 |
| Dec 31, 2025 | 24.72 Mn |
| Dec 31, 2024 | -15,000.00 |
| Sep 30, 2024 | -59,000.00 |
| Jun 30, 2024 | -757,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -1.58 Mn |
| Sep 30, 2023 | 239.98 Mn |
| Jun 30, 2023 | 16.30 Mn |
| Mar 31, 2023 | 10.23 Mn |
| Dec 31, 2022 | 19.81 Mn |
| Sep 30, 2022 | 14.41 Mn |
| Jun 30, 2022 | 12.99 Mn |
| Mar 31, 2022 | 5.78 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.64 Mn |
| Jun 30, 2021 | -39.01 Mn |
| Mar 31, 2021 | -53.87 Mn |
| Dec 31, 2020 | -121.62 Mn |
| Sep 30, 2020 | -22.55 Mn |